Cargando…
Case report: Novel junctional sarcoplasmic reticulum protein 1 intergenic region–anaplastic lymphoma kinase fusion in a patient with lung adenocarcinoma responds to alectinib
Novel anaplastic lymphoma kinase (ALK) fusions are still being discovered in non-small cell lung cancer (NSCLC). Most patients with ALK+ NSCLC respond favorably to ALK tyrosine kinase inhibitors. In this case report, we identified a novel nonreciprocal ALK fusion, namely, junctional sarcoplasmic ret...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9577405/ https://www.ncbi.nlm.nih.gov/pubmed/36267987 http://dx.doi.org/10.3389/fonc.2022.1019624 |
_version_ | 1784811749534334976 |
---|---|
author | Xue, Feng Xu, Shengyuan Jiang, Cailing Kang, Mafei Usman, Muhammad Zhu, Lin |
author_facet | Xue, Feng Xu, Shengyuan Jiang, Cailing Kang, Mafei Usman, Muhammad Zhu, Lin |
author_sort | Xue, Feng |
collection | PubMed |
description | Novel anaplastic lymphoma kinase (ALK) fusions are still being discovered in non-small cell lung cancer (NSCLC). Most patients with ALK+ NSCLC respond favorably to ALK tyrosine kinase inhibitors. In this case report, we identified a novel nonreciprocal ALK fusion, namely, junctional sarcoplasmic reticulum protein 1 (JSRP1) intergenic region–ALK fusion (Jintergenic: A20) via next-generation sequencing in a female patient initially diagnosed with stage IV B lung adenocarcinoma. Further examination of biopsy specimen and analysis of clinical samples by a multidisciplinary team confirmed the diagnosis of ALK+ NSCLC. At the 2- and 4-months follow-up after receiving alectinib, the patient responded rapidly, implying that alectinib had a remarkable therapeutic effect. We identified a novel JSRP1 intergenic region–ALK fusion as a carcinogenic mutation that responds to alectinib, thereby expanding the spectrum of ALK fusion partners in ALK + NSCLC. This study may help clinicians detect oncogenic mutations and provide timely treatment to patients with ALK+ NSCLC. |
format | Online Article Text |
id | pubmed-9577405 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95774052022-10-19 Case report: Novel junctional sarcoplasmic reticulum protein 1 intergenic region–anaplastic lymphoma kinase fusion in a patient with lung adenocarcinoma responds to alectinib Xue, Feng Xu, Shengyuan Jiang, Cailing Kang, Mafei Usman, Muhammad Zhu, Lin Front Oncol Oncology Novel anaplastic lymphoma kinase (ALK) fusions are still being discovered in non-small cell lung cancer (NSCLC). Most patients with ALK+ NSCLC respond favorably to ALK tyrosine kinase inhibitors. In this case report, we identified a novel nonreciprocal ALK fusion, namely, junctional sarcoplasmic reticulum protein 1 (JSRP1) intergenic region–ALK fusion (Jintergenic: A20) via next-generation sequencing in a female patient initially diagnosed with stage IV B lung adenocarcinoma. Further examination of biopsy specimen and analysis of clinical samples by a multidisciplinary team confirmed the diagnosis of ALK+ NSCLC. At the 2- and 4-months follow-up after receiving alectinib, the patient responded rapidly, implying that alectinib had a remarkable therapeutic effect. We identified a novel JSRP1 intergenic region–ALK fusion as a carcinogenic mutation that responds to alectinib, thereby expanding the spectrum of ALK fusion partners in ALK + NSCLC. This study may help clinicians detect oncogenic mutations and provide timely treatment to patients with ALK+ NSCLC. Frontiers Media S.A. 2022-10-04 /pmc/articles/PMC9577405/ /pubmed/36267987 http://dx.doi.org/10.3389/fonc.2022.1019624 Text en Copyright © 2022 Xue, Xu, Jiang, Kang, Usman and Zhu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Xue, Feng Xu, Shengyuan Jiang, Cailing Kang, Mafei Usman, Muhammad Zhu, Lin Case report: Novel junctional sarcoplasmic reticulum protein 1 intergenic region–anaplastic lymphoma kinase fusion in a patient with lung adenocarcinoma responds to alectinib |
title | Case report: Novel junctional sarcoplasmic reticulum protein 1 intergenic region–anaplastic lymphoma kinase fusion in a patient with lung adenocarcinoma responds to alectinib |
title_full | Case report: Novel junctional sarcoplasmic reticulum protein 1 intergenic region–anaplastic lymphoma kinase fusion in a patient with lung adenocarcinoma responds to alectinib |
title_fullStr | Case report: Novel junctional sarcoplasmic reticulum protein 1 intergenic region–anaplastic lymphoma kinase fusion in a patient with lung adenocarcinoma responds to alectinib |
title_full_unstemmed | Case report: Novel junctional sarcoplasmic reticulum protein 1 intergenic region–anaplastic lymphoma kinase fusion in a patient with lung adenocarcinoma responds to alectinib |
title_short | Case report: Novel junctional sarcoplasmic reticulum protein 1 intergenic region–anaplastic lymphoma kinase fusion in a patient with lung adenocarcinoma responds to alectinib |
title_sort | case report: novel junctional sarcoplasmic reticulum protein 1 intergenic region–anaplastic lymphoma kinase fusion in a patient with lung adenocarcinoma responds to alectinib |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9577405/ https://www.ncbi.nlm.nih.gov/pubmed/36267987 http://dx.doi.org/10.3389/fonc.2022.1019624 |
work_keys_str_mv | AT xuefeng casereportnoveljunctionalsarcoplasmicreticulumprotein1intergenicregionanaplasticlymphomakinasefusioninapatientwithlungadenocarcinomarespondstoalectinib AT xushengyuan casereportnoveljunctionalsarcoplasmicreticulumprotein1intergenicregionanaplasticlymphomakinasefusioninapatientwithlungadenocarcinomarespondstoalectinib AT jiangcailing casereportnoveljunctionalsarcoplasmicreticulumprotein1intergenicregionanaplasticlymphomakinasefusioninapatientwithlungadenocarcinomarespondstoalectinib AT kangmafei casereportnoveljunctionalsarcoplasmicreticulumprotein1intergenicregionanaplasticlymphomakinasefusioninapatientwithlungadenocarcinomarespondstoalectinib AT usmanmuhammad casereportnoveljunctionalsarcoplasmicreticulumprotein1intergenicregionanaplasticlymphomakinasefusioninapatientwithlungadenocarcinomarespondstoalectinib AT zhulin casereportnoveljunctionalsarcoplasmicreticulumprotein1intergenicregionanaplasticlymphomakinasefusioninapatientwithlungadenocarcinomarespondstoalectinib |